Crinetics (CRNX) Insider: 5,000-Share Option Exercise and Sale Under 10b5-1 Plan
Rhea-AI Filing Summary
Crinetics Pharmaceuticals (CRNX) reporting insider transactions by Dana Pizzuti. The filing shows on 09/02/2025 the reporting person acquired 5,000 shares of common stock by exercising options at an exercise price of $16.89 and simultaneously sold 5,000 shares in open-market transactions under a Rule 10b5-1 plan at a volume-weighted average price of $32.10 per share (range $32.00–$32.24). Following these transactions the reporting person beneficially owned 96,270 shares of common stock and directly held 84,042 shares underlying vested and unvested stock options that remain outstanding. The sale was effected automatically pursuant to a 10b5-1 trading plan adopted May 21, 2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Officer exercised options and sold equal shares under a pre-established 10b5-1 plan; transaction appears procedural, not a sudden disposition.
The report documents a contemporaneous option exercise at $16.89 per share and an open-market sale of the same number of shares at a VWAP of $32.10 on 09/02/2025. The sale was executed under a Rule 10b5-1 plan adopted 05/21/2025, indicating the transactions followed a pre-set trading arrangement. Post-transaction beneficial ownership is disclosed as 96,270 shares, and 84,042 option-derived shares remain outstanding. For investors, this clarifies the officer converted equity and recycled a portion into cash through an automated plan rather than an ad hoc sale.
TL;DR: Use of a documented 10b5-1 plan and attorney-in-fact signature show adherence to insider-trading controls and disclosure rules.
The Form 4 shows the reporting person is an officer (Chief Medical and Development Officer) and that the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025. The form is signed by an attorney-in-fact, consistent with delegated execution practices. These elements reflect compliance with Section 16 reporting and insider-trading safe-harbor procedures. The filing does not disclose any accelerated vesting, unusual compensation changes, or other governance issues.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $16.89 | $84K |
| Sale | Common Stock | 5,000 | $32.10 | $161K |
Footnotes (1)
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.10 per share. The range of sales prices on the transaction date was $32.00 to $32.24 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
